SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
87
|
THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD (ABSTRACT
12)
Harold W. Jaffe
Centers for Disease Control and Prevention, Atlanta, GA, USA
PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION (ABSTRACT
13)
JoAnne L Flynn
University of Pittsburgh, Pittsburgh, PA, USA
EFFECT OF TB SCREENING AND RETENTION INTERVENTIONS ON EARLY ART MORTALITY IN BOTSWANA (ABSTRACT
31)
Andrew Francis Auld
U.S. Centers for Disease Control and Prevention (CDC), Dulles, VA, USA
A CLUSTER-RANDOMIZED TRIAL OF SYMPTOM VS TST SCREENING TO IMPROVE CHILD IPT UPTAKE (ABSTRACT
32)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24 (ABSTRACT
33)
Kelly Dooley
Johns Hopkins University, Baltimore, MD, USA
PHARMACOKINETICS OF BICTEGRAVIR ADMINISTERED TWICE DAILY IN COMBINATION WITH RIFAMPIN (ABSTRACT
34)
Joseph M. Custodio
Gilead Science, Foster city, CA, USA
HIGHER HIGH DOSE FLUCONAZOLE FOR THE TREATMENT OF CRYPTOCOCCAL MENINGITIS (ABSTRACT
35)
Wadzanai Samaneka
Parirenyatwa Clinical Research Site, Harare, Zimbabwe
ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS (ABSTRACT
36)
Joshua Rhein
University of Minnesota, Minneapolis, MN, USA
ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN PEOPLE WITH HIV: BRIEF-TB/A5279 (ABSTRACT
37LB)
Richard E. Chaisson
Johns Hopkins University, Baltimore, MD, USA
URINE-BASED SCREENING FOR TUBERCULOSIS: A RANDOMIZED TRIAL IN HIV-POSITIVE INPATIENTS (ABSTRACT
38LB)
Ankur Gupta-Wright
London School of Hygiene & Tropical Medicine, London, United Kingdom
A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS (ABSTRACT
39LB)
Gustavo E Velásquez
Brigham and Women's Hospital, Boston, MA, USA
SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC (ABSTRACT
22)
Jean-Michel Molina
Hôpital Saint-Louis, Paris, France
IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL (ABSTRACT
23)
Diana Gibb
MRC Clinical Trials Unit at UCL, London, United Kingdom
HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG'S A5257 TRIAL (ABSTRACT
24)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION (ABSTRACT
25)
Jose R Castillo-Mancilla
University of Colorado, Denver, Aurora, CO, USA
MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV (ABSTRACT
26)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI) (ABSTRACT
27)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS (ABSTRACT
28LB)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL (ABSTRACT
29LB)
François-Xavier Blanc
l'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES (ABSTRACT
30LB)
Beatriz Grinsztejn
Fiocruz, Rio de Janeiro, Brasil, Brazil
RAPIDLY GROWING HIV TRANSMISSION CLUSTERS IN THE UNITED STATES, 2013–2016 (ABSTRACT
40)
Anne Marie France
Centers for Disease Control and Prevention, Atlanta, GA, USA
CLUSTER ANALYSIS REVEALS IMPORTANT SHIFT OF DRIVERS OF THE HIV EPIDEMIC IN SWISS MSM (ABSTRACT
41)
Nadine Bachmann
University Hospital Zurich, Zurich, Switzerland
PHYLOGENETIC PATTERNS OF HIV TRANSMISSION AMONG TRANSGENDER WOMEN IN LOS ANGELES (ABSTRACT
42)
Manon Ragonnet-Cronin
University of California, San Diego, San Diego, CA, USA
ASSESSING THE ROLE OF GEOGRAPHICAL HIV HOT-SPOTS IN THE SPREAD OF THE EPIDEMIC (ABSTRACT
43)
Diego F Cuadros
University of Cincinnati, Cincinnati, OH, USA
USING SUCCESSIVE SURVEYS TO CALCULATE INCIDENCE AMONG AT-RISK POPULATIONS IN THE US (ABSTRACT
44)
Janet Chuyun Burnett
Centers for Disease Control and Prevention, Atlanta, GA, USA
FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM (ABSTRACT
45)
Renee Heffron
University of Washington, Seattle, WA, USA
SHARP DECLINE IN MALE HIV INCIDENCE IN A RURAL SOUTH AFRICAN POPULATION (2004–2015) (ABSTRACT
46)
Alain Vandormael
University of KwaZulu-Natal, South Africa, Durban, KZN, South Africa
ONGOING HIV MICROEPIDEMICS IN RURAL SOUTH AFRICA: THE NEED FOR FLEXIBLE INTERVENTIONS (ABSTRACT
47LB)
Cordelia Coltart
University College London, London, United Kingdom
IDENTIFICATION OF A NOVEL LOCUS OF HIV REGULATION IN POPULATIONS OF AFRICAN DESCENT (ABSTRACT
14)
Paul J McLaren
Public Health Agency of Canada, WInnipeg, Canada
HOST FACTORS ASSOCIATED WITH BNAB DEVELOPMENT IN HIV-1 CONTROLLERS (ABSTRACT
15)
Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
INTERDOMAIN STABILIZATION IMPAIRS CD4 BINDING AND IMPROVES IMMUNOGENICITY OF SOSIPS (ABSTRACT
16LB)
Peng Zhang
NIH, Bethesda, MD, USA
EQUAL DISTRIBUTION OF SIV DNA IN MEMORY T HELPER CELL SUBSETS OF RHESUS MACAQUES (ABSTRACT
17)
Stephen Lai
NIH, Bethesda, MD, USA
KINETICS OF GASTROINTESTINAL DYSFUNCTION IN ACUTE SIV INFECTION OF MACAQUES (ABSTRACT
18)
Tiffany Hensley-McBain
University of Washington, Seattle, WA, USA
PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART (ABSTRACT
19)
Claire Deleage
NIH, Frederick National Laboratory for Cancer Research, Frederick, USA
P38 MAPK IN VIVO INHIBITION IMPACTS SIV-MEDIATED IMMUNE ACTIVATION & CD4 T-CELL LOSS (ABSTRACT
20)
Anna Aldovini
Boston Children's Hospital, Boston, MA, USA
INTRON−CONTAINING HIV−1 RNA ACTIVATES TYPE I INTERFERON AND INFLAMMATORY CYTOKINES (ABSTRACT
21)
Sean McCauley
University of Massachusetts Medical School, Worcester, MA, USA
DRUG-DRUG INTERACTIONS IN HIV-ASSOCIATED TB: BALANCING EVIDENCE, RISK, AND PRAGMATISM (ABSTRACT
1159)
Gary Maartens
University of Cape Town, Cape Town , South Africa
EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE (ABSTRACT
455)
Anthony Podany
University of Nebraska, Omaha, NE, USA
EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS (ABSTRACT
456)
Daniel Warren Atwine
MSF-Epicentre, Mbarara, Uganda
PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV (ABSTRACT
457)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN (ABSTRACT
458)
Rajith Kumar Reddy Rajoli
University of Liverpool, Liverpool, Merseyside, United Kingdom
THEMED DISCUSSION MODERATOR
Viviana A. Simon
Icahn School of Medicine at Mt Sinai, New York, NY, USA
NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS (ABSTRACT
186)
Rodrigo Matus-Nicodemos
Vaccine Research Center, NIAID, NIH, Bethesda, USA
HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET (ABSTRACT
185)
Anamaria Daniela Sarca
Kyoto University, Kyoto, Kyoto, Japan
VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY (ABSTRACT
187)
Frauke Christ
Katholieke University Leuven, Leuven, Belgium
UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1 (ABSTRACT
189)
Edmund Osei-Kuffour
Heinrich-Heine-University Hospital, Düsseldorf, Germany
VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER (ABSTRACT
190)
Sarah B Nodder
Boston University, Boston, MA, USA
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
87
|
